Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Novo Nordisk A/S has logged a -20.1% 52 week change, compared to 25.4% for the S&P 500 NVO has an average analyst rating of buy and is -26.9% away from its mean target price of $120.67 per share ...
The Capital Structure page of Vedanta Ltd. presents the Authorized Capital, Issued Capital, and Paid-Up Equity Capital of the company over the period.
The Capital Structure page of Mahindra & Mahindra Ltd. presents the Authorized Capital, Issued Capital, and Paid-Up Equity Capital of the company over the period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback